CS23546
Phase 1Small molecule
CS23546 is one of 35 small molecule programs targeting Advanced. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
46 competitors in Advanced
#DrugCompanyPhaseTrials
1Remodulin
United TherapeuticsPhase 3
Tecentriq
RochePhase 2
Qinlock
DDeciphera Pharmaceuticals, LLC
Phase 3
Lenvima
EisaiPhase 2
Fludara
SanofiPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Nolvadex
AstraZenecaPhase 2
Avastin
RochePhase 2
Libtayo
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CS23546. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CChipscreen Biosciences, Ltd.